RP101 demonstrates efficacy and safety in Phase II study of patients with moderate-to-severe dry eye disease
· RP101 more than doubles tear fluid production · Fast onset: statistically significant efficacy after just 14 days · All objective and subjective parameters show improvement Stockholm, Sweden, March 12, 2020 - Redwood Pharma announces today significant improvement of objective and subjective endpoints in the Phase II study in postmenopausal women with moderate-to-severe dry eye. RP101 more than doubles tear fluid production. The objective Schirmer test reached 9.6 mm compared to the nominal 10 mm goal for the primary endpoint. Further objective and subjective endpoints demonstrate